Israel (Rudi) Rubinstein
Professor of Medicine
College of Medicine
University of Illinois at Chicago
Rubinstein is Professor of Medicine at the College of Medicine, University of Illinois at Chicago. He is member of the Section of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of Illinois at Chicago and Attending Physician at the University of Illinois Hospital & Health Sciences System and Jesse Brown VA Medical Center, Chicago, Illinois, U.S.A. He is also the Associate Chief of Staff for Research and Development at the Jesse Brown VA Medical Center, Chicago, Illinois, U.S.A. Rubinstein received his medical degree from the Hebrew University–Hadassah School of Medicine in Jerusalem. He was medical resident in Israel, fellow in respirology at the University of Toronto and research fellow at the Cardiovascular Research Institute, University of California at San Francisco. Dr. Rubinstein is board certified in pulmonary disease. He holds 18 issued and pending U.S. and international patents and has authored more than 190 peer-reviewed articles in scientific journals. Rubinstein’s research interests include nanomedicine, targeted drug delivery, and bioimaging. He is Editor-in-Chief of Nanotechnology, Science and Applications, Associate Editor of International Journal of Nanomedicine and member of the Editorial Board of several scientific journals. Dr. Rubinstein is member of the Scientific Advisory Board of the International Academy of Cardiology. He is Fellow of the American Heart Association, American College of Physicians and American College of Chest Physicians. In addition, he is member of the American Thoracic Society, American Physiological Society, American Society for Pharmacology and Experimental Therapeutics, American Microbiology Society and Microcirculatory Society. Dr. Rubinstein is Board Member and Director of Advanced Life Sciences, a publicly-traded biopharmaceutical company in Woodridge, Illinois, U.S.A. He co-founded ResQ Pharma, an emerging clinical stage pharmaceutical company focusing on repurposing FDA-approved drugs for cardiopulmonary resuscitation and drug overdoses.
Rubinstein’s research interests include nanomedicine, targeted drug delivery, and bioimaging.